HYBRID EVENT: You can participate in person at Valencia, Spain or Virtually from your home or work.
COVID-19 Drug Development
COVID-19 drug development is a research process to discover a preventative and therapeutic prescription of drugs that would control the severity of coronavirus disease. From 2020 to 2021, various drug companies, biotechnology firms, university research groups, and health organizations were started developing over 600 potential therapies for corona virus disease with various stages of preclinical or clinical research, with 391 therapeutic candidates in clinical trials, as of January 2021.
Committee Members
Saad Tayyab
UCSI University, Malaysia
Consolato M Sergi
Universities of Alberta and Ottawa, Canada
Sergey Suchkov
The Russian University of Medicine and Russian Academy of Natural Science-Moscow, Russian Federation
Marino Nebuloni
University of Insubria, Italy PDDS 2025 Speakers
Consolato M Sergi
Universities of Alberta and Ottawa, Canada
Sergey Suchkov
The Russian University of Medicine and Russian Academy of Natural Science-Moscow, Russian Federation
Marino Nebuloni
University of Insubria, Italy
Saad Tayyab
UCSI University, MalaysiaSubmit your abstract Today
Title : Medical liver Biopsy: Toward a personalized approach
Consolato M Sergi, Universities of Alberta and Ottawa, Canada
Title : Macitentan/Tadalafil Combination– An additional value in pharmacotherapy of pulmonary arterial hypertension
Miroslav Radenkovic, University of Belgrade, Serbia